GlassScriptPhysician profile
Ndidi Obiefuna
NPI 1225602790
$1,806.25
in general payments reported to CMS, 2019-2025
14 companies · $828 in 2025
The $828 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $237 · 2023: $132 · 2024: $609 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.84 | 2024-2025 | Airsupra |
| Teva Pharmaceuticals USA, INC. | $221.09 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $167.33 | 2025 | Rexulti |
| Edwards Lifesciences Corporation | $152.58 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Tempus Ai, INC | $124.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.07 | 2022 | |
| Exeltis, USA INC. | $123.98 | 2025 | |
| Amgen INC. | $113.75 | 2024 | Repatha |
| Antares Pharma, INC. | $112.63 | 2022 | |
| Novo Nordisk INC | $111.83 | 2025 | Ozempic |
| Axsome Therapeutics, INC. | $102.11 | 2025 | Auvelity |
| Coloplast Corp | $75.22 | 2025 | |
| Averitas Pharma INC. | $70.00 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ndidi Obiefuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.